Food and Drug Administration
Arthritis Advisory Committee
August 16, 2001
BLA STN 103950 Kineret® , (anakinra), Amgen, Inc.
FDA Perspective, Raymond P. Donnelly, Ph.D. ppt htm
Biologic License Application: anakinra (KINERET) for
rheumatoid arthritis, CBER ppt
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Amgen Inc. Presentation ppt pdf